Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -61570.00% is 1386% below its 4-year average of -4144.58%, near the low end of its 4-year range (-78450.00%–0.00%).
25.32% below its 12-month average of -49130.00%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2025 (2025-03-31): -19810.00%.
EBITDA MARGIN
-61570.00%
EBITDA MARGIN AVG TTM
-49130.00%
EBITDA MARGIN AVG 3Y
-12818.50%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-25.32%
CURRENT VS 3Y AVG
-380.32%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
INmune Bio, Inc.
Market Cap
$50.51M
EBITDA Margin
-61570.00%
TTM Avg
-49130.00%
3Y Avg
-12818.50%
5Y Avg
N/A
Market Cap
$50.80M
EBITDA Margin
-203.44%
TTM Avg
-129.78%
3Y Avg
-288.25%
5Y Avg
-438.27%
Market Cap
$50.96M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
Market Cap
$50.07M
EBITDA Margin
-36.23%
TTM Avg
-36.23%
3Y Avg
-36.23%
5Y Avg
-36.23%
Market Cap
$49.90M
EBITDA Margin
-30422.22%
TTM Avg
-16673.71%
3Y Avg
-8702.25%
5Y Avg
-6477.94%
Market Cap
$49.89M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
Market Cap
$51.32M
EBITDA Margin
-2290.88%
TTM Avg
-3688.53%
3Y Avg
-3688.53%
5Y Avg
-3177.84%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| INmune Bio, Inc. (INMB) | $50.51M | -61570.00% | -49130.00% | -12818.50% | N/A |
| Celularity Inc. (CELU)vs › | $50.80M | -203.44% | -129.78% | -288.25% | -438.27% |
| Envoy Medical, Inc. (COCH)vs › | $50.96M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.07M | -36.23% | -36.23% | -36.23% | -36.23% |
| Microbot Medical Inc. (MBOT)vs › | $49.90M | -30422.22% | -16673.71% | -8702.25% | -6477.94% |
| Apollomics, Inc. (APLM)vs › | $49.89M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.32M | -2290.88% | -3688.53% | -3688.53% | -3177.84% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.61M | 20.40% | 19.12% | 4.66% | 12.12% |
| Clene Inc. (CLNN)vs › | $51.62M | -10794.00% | -9994.66% | -8986.60% | -8678.68% |
Gross Margin
100.0%
EBITDA Margin
-61570.0%
Operating Margin
-61738.0%
Net Margin
-91866.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-03-31 | -19810.00% |
| 2024-03-31 | -78450.00% |
| 2023-12-31 | -29925.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | -64435.71% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
